Would you consider PD-L1 score when deciding whether to incorporate durvalumab in first-line metastatic biliary cancer?

Do you utilize biomarker/molecular testing for advanced biliary tract cancers?

• I obtain broad molecular sequencing on all patients up front
• I obtain broad molecular sequencing once patient has progressed on standard therapies
• I test for a smaller panel of select biomarkers on all patients up front
• I test for a smaller panel of select biomarkers once patient has progressed on standard therapies
• I test only for PDL1/TMB on all patients up front
• I test only for PDL1/TMB once patient has progressed on standard therapies
• I don't routinely obtain biomarker/molecular testing in BTCs
• Other